TONIX PHARMACEUTICALS HOLDIN (TNXP) Stock Fundamental Analysis

NASDAQ:TNXP • US8902608392

13.97 USD
-0.46 (-3.19%)
At close: Feb 27, 2026
13.92 USD
-0.05 (-0.36%)
After Hours: 2/27/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall TNXP gets a fundamental rating of 3 out of 10. We evaluated TNXP against 521 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for TNXP as it has an excellent financial health rating, but there are worries on the profitability. TNXP does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year TNXP has reported negative net income.
  • TNXP had a negative operating cash flow in the past year.
  • In the past 5 years TNXP always reported negative net income.
  • TNXP had a negative operating cash flow in each of the past 5 years.
TNXP Yearly Net Income VS EBIT VS OCF VS FCFTNXP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

  • TNXP's Return On Assets of -39.30% is in line compared to the rest of the industry. TNXP outperforms 58.73% of its industry peers.
  • With a decent Return On Equity value of -42.93%, TNXP is doing good in the industry, outperforming 69.29% of the companies in the same industry.
Industry RankSector Rank
ROA -39.3%
ROE -42.93%
ROIC N/A
ROA(3y)-69.05%
ROA(5y)-59.72%
ROE(3y)-86.71%
ROE(5y)-72.38%
ROIC(3y)N/A
ROIC(5y)N/A
TNXP Yearly ROA, ROE, ROICTNXP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

  • The Gross Margin of TNXP (34.31%) is better than 73.70% of its industry peers.
  • The Profit Margin and Operating Margin are not available for TNXP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 34.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TNXP Yearly Profit, Operating, Gross MarginsTNXP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • TNXP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for TNXP has been increased compared to 1 year ago.
  • TNXP has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for TNXP has been reduced compared to a year ago.
TNXP Yearly Shares OutstandingTNXP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
TNXP Yearly Total Debt VS Total AssetsTNXP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of 0.34, we must say that TNXP is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of TNXP (0.34) is better than 60.84% of its industry peers.
  • TNXP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.34
ROIC/WACCN/A
WACC8.75%
TNXP Yearly LT Debt VS Equity VS FCFTNXP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 9.89 indicates that TNXP has no problem at all paying its short term obligations.
  • TNXP has a Current ratio of 9.89. This is amongst the best in the industry. TNXP outperforms 80.81% of its industry peers.
  • TNXP has a Quick Ratio of 9.62. This indicates that TNXP is financially healthy and has no problem in meeting its short term obligations.
  • TNXP has a Quick ratio of 9.62. This is amongst the best in the industry. TNXP outperforms 80.61% of its industry peers.
Industry RankSector Rank
Current Ratio 9.89
Quick Ratio 9.62
TNXP Yearly Current Assets VS Current LiabilitesTNXP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 99.62% over the past year.
  • TNXP shows a decrease in Revenue. In the last year, the revenue decreased by -8.79%.
EPS 1Y (TTM)99.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.39%
Revenue 1Y (TTM)-8.79%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%16.58%

3.2 Future

  • Based on estimates for the next years, TNXP will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.91% on average per year.
  • Based on estimates for the next years, TNXP will show a very strong growth in Revenue. The Revenue will grow by 72.02% on average per year.
EPS Next Y99.46%
EPS Next 2Y41.31%
EPS Next 3Y25.97%
EPS Next 5Y18.91%
Revenue Next Year-16.25%
Revenue Next 2Y160.19%
Revenue Next 3Y92.27%
Revenue Next 5Y72.02%

3.3 Evolution

TNXP Yearly Revenue VS EstimatesTNXP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 20M 40M 60M 80M 100M
TNXP Yearly EPS VS EstimatesTNXP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -500M -1B -1.5B

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • TNXP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TNXP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TNXP Price Earnings VS Forward Price EarningsTNXP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TNXP Per share dataTNXP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 -20

4.3 Compensation for Growth

  • TNXP's earnings are expected to grow with 25.97% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.31%
EPS Next 3Y25.97%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • TNXP does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TONIX PHARMACEUTICALS HOLDIN

NASDAQ:TNXP (2/27/2026, 8:00:02 PM)

After market: 13.92 -0.05 (-0.36%)

13.97

-0.46 (-3.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-16
Inst Owners20.51%
Inst Owner Change49.28%
Ins Owners0.06%
Ins Owner Change0%
Market Cap178.68M
Revenue(TTM)10.30M
Net Income(TTM)-99.22M
Analysts82.5
Price Target67.66 (384.32%)
Short Float %18.24%
Short Ratio4.96
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.94%
Min EPS beat(2)-17.71%
Max EPS beat(2)1.82%
EPS beat(4)3
Avg EPS beat(4)23.86%
Min EPS beat(4)-17.71%
Max EPS beat(4)97.53%
EPS beat(8)6
Avg EPS beat(8)-23.28%
EPS beat(12)8
Avg EPS beat(12)-14.25%
EPS beat(16)10
Avg EPS beat(16)-8.72%
Revenue beat(2)1
Avg Revenue beat(2)-7.73%
Min Revenue beat(2)-19.5%
Max Revenue beat(2)4.05%
Revenue beat(4)1
Avg Revenue beat(4)-12.44%
Min Revenue beat(4)-27.68%
Max Revenue beat(4)4.05%
Revenue beat(8)1
Avg Revenue beat(8)-17.18%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.97%
EPS NQ rev (1m)-0.95%
EPS NQ rev (3m)23.59%
EPS NY rev (1m)-0.55%
EPS NY rev (3m)-2.28%
Revenue NQ rev (1m)2.89%
Revenue NQ rev (3m)-17.97%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.78%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 17.35
P/FCF N/A
P/OCF N/A
P/B 0.77
P/tB 0.77
EV/EBITDA N/A
EPS(TTM)-20.06
EYN/A
EPS(NY)-7.95
Fwd EYN/A
FCF(TTM)-5.97
FCFYN/A
OCF(TTM)-5.85
OCFYN/A
SpS0.81
BVpS18.07
TBVpS18.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -39.3%
ROE -42.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 34.31%
FCFM N/A
ROA(3y)-69.05%
ROA(5y)-59.72%
ROE(3y)-86.71%
ROE(5y)-72.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 77.5%
Cap/Sales 14.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.89
Quick Ratio 9.62
Altman-Z 0.34
F-Score5
WACC8.75%
ROIC/WACCN/A
Cap/Depr(3y)1346.5%
Cap/Depr(5y)20638.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.39%
EPS Next Y99.46%
EPS Next 2Y41.31%
EPS Next 3Y25.97%
EPS Next 5Y18.91%
Revenue 1Y (TTM)-8.79%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%16.58%
Revenue Next Year-16.25%
Revenue Next 2Y160.19%
Revenue Next 3Y92.27%
Revenue Next 5Y72.02%
EBIT growth 1Y-20.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y33.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.61%
OCF growth 3YN/A
OCF growth 5YN/A

TONIX PHARMACEUTICALS HOLDIN / TNXP FAQ

What is the fundamental rating for TNXP stock?

ChartMill assigns a fundamental rating of 3 / 10 to TNXP.


What is the valuation status of TONIX PHARMACEUTICALS HOLDIN (TNXP) stock?

ChartMill assigns a valuation rating of 1 / 10 to TONIX PHARMACEUTICALS HOLDIN (TNXP). This can be considered as Overvalued.


How profitable is TONIX PHARMACEUTICALS HOLDIN (TNXP) stock?

TONIX PHARMACEUTICALS HOLDIN (TNXP) has a profitability rating of 1 / 10.